Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Syndax Pharmaceuticals (SNDX) Tops Q1 EPS by 11c, Revenues Beat
May 11, 2021 4:40 PM EDTSyndax Pharmaceuticals (NASDAQ: SNDX) reported Q1 EPS of ($0.54), $0.11 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $379 thousand versus the consensus estimate of $220 thousand.
"We are excited to provide an update on the positive interim Phase 1 data from the ongoing AUGMENT-101 trial of SNDX-5613 in patients with mixed lineage leukemia rearranged (MLLr) and nucleophosmin (NPM1c) mutant acute leukemias," said... More
